Tina Primeau YOU? Author Swipe

Last 10y

Neratinib Synergizes with Trastuzumab Antibody Drug Conjugate or with Vinorelbine to Treat HER2 Mutated Breast Cancer Patient Derived Xenografts and Organoids Open

Shunqiang Li, Tina Primeau, Maureen Highkin, Stephanie L. Pratt, Ashley R. Tipton , et al. · 2023

HER2 ( ERBB2 ) is a major therapeutic drug target in breast cancer and The Cancer Genome Atlas (TCGA) Breast Cancer project and other studies have identified HER2 activating mutations in breast cancers without HER2 gene amplification. HER2…

Table S1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Clinical information for the patients and corresponding tumors

Table S2 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Somatic mutations and copy number alterations for the tumors

Table S5 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Tumor volumes after 1-month and 2-month treatments

Supplementary Data 1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Tumor size and body weight measurements by day

Supplementary Figures from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Supplementary Figure S1-5

Table S3 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Treatments received by the patients

Table S4 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Statistical tests for tumor volume changes

Table S5 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Tumor volumes after 1-month and 2-month treatments

Table S3 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Treatments received by the patients

Supplementary Figures from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Supplementary Figure S1-5

Table S1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Clinical information for the patients and corresponding tumors

Supplementary Data 1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Tumor size and body weight measurements by day

Data from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Current treatment approaches for renal cell carcinoma (RCC) face challenges in achieving durable tumor responses due to tumor heterogeneity and drug resistance. Combination therapies that leverage tumor molecular profiles could offer an av…

Table S4 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Statistical tests for tumor volume changes

Table S2 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Somatic mutations and copy number alterations for the tumors

Data from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Current treatment approaches for renal cell carcinoma (RCC) face challenges in achieving durable tumor responses due to tumor heterogeneity and drug resistance. Combination therapies that leverage tumor molecular profiles could offer an av…

Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma Open

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal , et al. · 2023

Current treatment approaches for renal cell carcinoma (RCC) face challenges in achieving durable tumor responses due to tumor heterogeneity and drug resistance. Combination therapies that leverage tumor molecular profiles could offer an av…

Figure S1 from Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer Open

Shuying Liu, Shunqiang Li, Bailiang Wang, Wenbin Liu, Mihai Gagea , et al. · 2023

MET gene constructs

Supplementary Table 2 from Breast Cancer Neoantigens Can Induce CD8<sup>+</sup> T-Cell Responses and Antitumor Immunity Open

Xiuli Zhang, Samuel Kim, Jasreet Hundal, John M. Herndon, Shunqiang Li , et al. · 2023

Characterization of tier 1 mutations identified in WHIM30 through NSG.

Supplementary Figures 1 - 5, Tables 1, 5 - 9 from Breast Cancer Neoantigens Can Induce CD8<sup>+</sup> T-Cell Responses and Antitumor Immunity Open

Xiuli Zhang, Samuel Kim, Jasreet Hundal, John M. Herndon, Shunqiang Li , et al. · 2023

Supplementary Figure 1. H&E of WHIM30, WHIM35 and WHIM37 parental tumors. Supplementary Figure 2. Peptides corresponding to prioritized neoantigens can induce strong surface expression of HLA class I molecules. Supplementary Figure 3. Indi…

Figure S2 from Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer Open

Shuying Liu, Shunqiang Li, Bailiang Wang, Wenbin Liu, Mihai Gagea , et al. · 2023

Serum HGF in hHGF Tg/SCID mice

Figure S6 from Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer Open

Shuying Liu, Shunqiang Li, Bailiang Wang, Wenbin Liu, Mihai Gagea , et al. · 2023

Effect of HGF on cell signaling in MET-Y1253D/PIK3CA-H1047R cells

Data from Breast Cancer Neoantigens Can Induce CD8<sup>+</sup> T-Cell Responses and Antitumor Immunity Open

Xiuli Zhang, Samuel Kim, Jasreet Hundal, John M. Herndon, Shunqiang Li , et al. · 2023

Next-generation sequencing technologies have provided insights into the biology and mutational landscape of cancer. Here, we evaluate the relevance of cancer neoantigens in human breast cancers. Using patient-derived xenografts from three …

Figure S5A from Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer Open

Shuying Liu, Shunqiang Li, Bailiang Wang, Wenbin Liu, Mihai Gagea , et al. · 2023

Effect of HGF on cell signaling

Figure S5A from Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer Open

Shuying Liu, Shunqiang Li, Bailiang Wang, Wenbin Liu, Mihai Gagea , et al. · 2023

Effect of HGF on cell signaling

Figure S6 from Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer Open

Shuying Liu, Shunqiang Li, Bailiang Wang, Wenbin Liu, Mihai Gagea , et al. · 2023

Effect of HGF on cell signaling in MET-Y1253D/PIK3CA-H1047R cells

Supplementary Figures 1 - 5, Tables 1, 5 - 9 from Breast Cancer Neoantigens Can Induce CD8<sup>+</sup> T-Cell Responses and Antitumor Immunity Open

Xiuli Zhang, Samuel Kim, Jasreet Hundal, John M. Herndon, Shunqiang Li , et al. · 2023

Supplementary Figure 1. H&E of WHIM30, WHIM35 and WHIM37 parental tumors. Supplementary Figure 2. Peptides corresponding to prioritized neoantigens can induce strong surface expression of HLA class I molecules. Supplementary Figure 3. Indi…

Table S1 from Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer Open

Shuying Liu, Shunqiang Li, Bailiang Wang, Wenbin Liu, Mihai Gagea , et al. · 2023

Antibody list

Supplementary Table 2 from Breast Cancer Neoantigens Can Induce CD8<sup>+</sup> T-Cell Responses and Antitumor Immunity Open

Xiuli Zhang, Samuel Kim, Jasreet Hundal, John M. Herndon, Shunqiang Li , et al. · 2023

Characterization of tier 1 mutations identified in WHIM30 through NSG.

Fetching topic information...